Relationship of P-selectin glycoprotein ligand-1 to prognosis in patients with multiple myeloma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 3, 2015, Pages 164-170

  Atalay, Figen ^a   Ateşoʇlu, Elif Birtaş ^b   Yildiz, Semsi ^a   Firatli Tuglular, Tülin ^c   Karakuş, Sema ^a   Bayik, Mahmut ^d  

^a BASKENT UNIVERSITY   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d Academic Hospital   (Turkey)

Author keywords

CD162; Immunocytochemistry; Multiple myeloma; P selectin ligand protein; Prognosis

Indexed keywords

ALBUMIN; BORTEZOMIB; CALCIUM; CREATININE; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; MELPHALAN; P SELECTIN GLYCOPROTEIN LIGAND 1; PREDNISOLONE; THALIDOMIDE; VINCRISTINE; MEMBRANE PROTEIN; P-SELECTIN LIGAND PROTEIN;

AGED; ALBUMIN BLOOD LEVEL; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW BIOPSY; CALCIUM BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CREATININE BLOOD LEVEL; DRUG MEGADOSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; BONE MARROW; CANCER GRADING; CANCER STAGING; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME;

AGED; BONE MARROW; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84923380234     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.09.005     Document Type: Article

References (24)

1. R.A. Kyle, and S.V. Rajkumar Plasma cell disorders L. Goldman, D.A. Ausiello, Cecil Textbook of Medicine 22nd ed 2004 WB Saunders Philadelphia 1184 1195
2. S.K. Kumar, S.V. Rajkumar, and A. Dispenzieri Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2008 2516 2520
3. S.V. Rajkumar, and P.R. Greipp Prognostic factors in multiple myeloma Hematol Oncol Clin North Am 13 1999 1295 1314
4. P. Tosi, B. Gamberi, and N. Giuliani Biology and treatment of multiple myeloma Biol Blood Marrow Transplant 12 2006 81 86
5. W.S. Dalton The tumor microenvironment: focus on myeloma Cancer Treat Rev 291 2003 11 19
6. K.C. Anderson Plasma cell tumors R.C. Bast Jr. D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, J.E. Holland, E. Frei III Cancer Medicine 5th ed. 2001 BC Decker Hamilton, Ontario 2066 2085
7. G.S. Kansas Selectins and their ligands: current concepts and controversies Blood 88 1996 3259 3287
8. K.H. Shain, T.H. Landowski, and W.S. Dalton The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance Curr Opin Oncol 126 2000 557 563
9. M. Chen, and J.G. Geng P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis Arch Immunol Ther Exp 54 2006 75 84
10. R.P. McEver, and R.D. Cummings Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment J Clin Invest 100 1997 485 491
11. A.C. Zannettino, M.C. Berndt, C. Butcher, E.C. Butcher, M.A. Vadas, and P.J. Simmons Primitive human hematopoietic progenitors adhere to P-selectin (CD62P) Blood 85 1995 3466 3477
12. A.M. Florena, C. Tripodo, L. Miceli, S. Ingrao, R. Porcasi, and V. Franco Identification of CD162 in plasma-cell dyscrasia Lancet Oncol 6 2005 632
13. K.V. Honn, D.G. Tang, and J.D. Crissman Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 11 1992 325 351
14. C.J. Dimitroff, L. Descheny, and N. Trujillo Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1 on human metastatic prostate tumor cells Cancer Res 65 2005 5750 5760
15. A.K. Azab, P. Quang, and F. Azab P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment Blood 119 2012 1468 1478
16. W.J. Chng, S. Kumar, and S. Vanwier Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling Cancer Res 677 2007 2982 2989
17. P.R. Greipp, J. San Miguel, and B.G. Durie International staging system for multiple myeloma J Clin Oncol 23 2005 3412 3420
18. R.A. Kyle, M.A. Gertz, and T.E. Witzig Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 2003 21 33
19. E. Zamagni, F. Patriarca, and C. Nanni Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation Blood 118 2011 5989 5995
20. J.A. Child, G.J. Morgan, F.E. Davies, R.G. Owen, S.E. Bell, and K. Hawkins High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma N Engl J Med 348 2003 1875 1883
21. S.V. Rajkumar, G. Gahrton, and P.L. Bergsagel Approach to the treatment of multiple myeloma: a clash of philosophies Blood 118 2011 3205 3211
22. R. Bataille, M. Jourdan, X.G. Zhang, and B. Klein Serum levels of interleukin 6: a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias J Clin Invest 84 1989 2008 2011
23. H. Ludwig, D.M. Nachbaur, E. Fritz, M. Krainer, and H. Huber Interleukin-6 is a prognostic factor in multiple myeloma Blood 77 1991 2794 2795
24. S.V. Rajkumar, T. Leong, and P.C. Roche Prognostic value of bone marrow angiogenesis in multiple myeloma Clin Cancer Res 6 2000 3111 3116